SOPHiA GENETICS (NASDAQ:SOPH) CTO Abhimanyu Verma Sells 5,000 Shares of Stock

Posted by Francis Steltz on Aug 6th, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) CTO Abhimanyu Verma sold 5,000 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $6.95, for a total value of $34,750.00. Following the transaction, the chief technology officer owned 187,171 shares in the company, valued at approximately $1,300,838.45. This trade represents a 2.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.10, for a total value of $26,953.50.
On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total transaction of $38,261.44.

SOPHiA GENETICS Stock Performance

Shares of SOPH stock opened at $6.30 on Thursday. The firm has a market capitalization of $528.51 million, a price-to-earnings ratio of -5.48 and a beta of 0.96. SOPHiA GENETICS SA has a 12 month low of $2.96 and a 12 month high of $7.21. The business’s 50-day moving average price is $5.54 and its 200-day moving average price is $5.12. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 153.15% and a negative net margin of 93.86%.The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. Equities research analysts forecast that SOPHiA GENETICS SA will post -0.58 EPS for the current year.

Wall Street Analyst Weigh In

SOPH has been the topic of several research reports. HC Wainwright upped their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday. BTIG Research boosted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Read Our Latest Research Report on SOPHiA GENETICS

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

Positive Sentiment: SOPHiA GENETICS raised its 2026 revenue outlook to $94 million–$96 million, above the approximately $93.4 million consensus estimate, implying 22%–24% year-over-year growth. Management also continues to target adjusted EBITDA breakeven by year-end. 2026 revenue outlook and EBITDA breakeven article
Positive Sentiment: The company announced a multi-year global collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The agreement could expand SOPH’s role in oncology testing and support longer-term revenue growth. AstraZeneca collaboration article
Positive Sentiment: HC Wainwright raised its price target from $12 to $14 and maintained a Buy rating, while BTIG lifted its target from $8 to $9 and also kept a Buy rating. The revisions indicate improving analyst confidence in SOPH’s growth outlook. Analyst price target updates
Positive Sentiment: Second-quarter revenue increased 27% year over year to $23.3 million, exceeding expectations of $21.7 million, while the adjusted EBITDA loss improved 27% to $8.8 million. Second-quarter 2026 results article
Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu collectively sold 35,000 shares for about $242,350 under pre-arranged Rule 10b5-1 plans. The sales reduced their holdings only modestly, limiting their signaling value.
Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, missing the $0.21-loss consensus estimate by $0.05. Net loss remained $22.4 million, and gross margin declined from the prior-year period, underscoring continuing profitability concerns. Quarterly earnings report

Institutional Trading of SOPHiA GENETICS

Institutional investors and hedge funds have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after buying an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC raised its position in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after buying an additional 1,481,636 shares during the last quarter. Principal Financial Group Inc. lifted its stake in SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after acquiring an additional 9,800 shares in the last quarter. Archon Capital Management LLC boosted its holdings in SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after acquiring an additional 14,342 shares during the last quarter. Finally, Hodges Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS in the 1st quarter worth $2,157,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.